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Abstract
Glycine receptors (GlyRs) are transmitter-gated anion channels of the Cys-loop superfamily which mediate synaptic
inhibition at spinal and selected supraspinal sites. Although they serve pivotal functions in motor control and sensory
processing, they have yet to be exploited as drug targets partly because of hitherto limited possibilities for allosteric control.
Endocannabinoids (ECs) have recently been characterized as direct allosteric GlyR modulators, but the underlying molecular
sites have remained unknown. Here, we show that chemically neutral ECs (e.g. anandamide, AEA) are positive modulators of
a1, a2 and a3 GlyRs, whereas acidic ECs (e.g. N-arachidonoyl-glycine; NA-Gly) potentiate a1 GlyRs but inhibit a2 and a3. This
subunit-specificity allowed us to identify the underlying molecular sites through analysis of chimeric and mutant receptors.
We found that alanine 52 in extracellular loop 2, glycine 254 in transmembrane (TM) region 2 and intracellular lysine 385
determine the positive modulation of a1 GlyRs by NA-Gly. Successive substitution of non-conserved extracellular and TM
residues in a2 converted NA-Gly-mediated inhibition into potentiation. Conversely, mutation of the conserved lysine within
the intracellular loop between TM3 and TM4 attenuated NA-Gly-mediated potentiation of a1 GlyRs, without affecting
inhibition of a2 and a3. Notably, this mutation reduced modulation by AEA of all three GlyRs. These results define molecular
sites for allosteric control of GlyRs by ECs and reveal an unrecognized function for the TM3-4 intracellular loop in the
allosteric modulation of Cys-loop ion channels. The identification of these sites may help to understand the physiological
role of this modulation and facilitate the development of novel therapeutic approaches to diseases such as spasticity, startle
disease and possibly chronic pain.
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Introduction
Glycine receptors (GlyRs) are anion-selective transmitter-
gated ion channels of the Cys-loop superfamily. They are
critical for the control of excitability in the spinal cord, brain
stem, and a few select brain areas. Diminished glycinergic
inhibition plays a key role in inflammation-induced pain
hypersensitivity and in heritable startle disease [1–3]. GlyRs
are pentameric complexes composed of a and b subunits,
which can form homomeric (a) or heteromeric (ab) receptors.
Each subunit possesses an amino-terminal extracellular do-
main (ECD), four transmembrane domains (TM) and a large
intracellular loop (IL) between TM3 and TM4 [3–4].
Molecular cloning studies have identified four highly con-
served a subunits (a1-4), which differ in their developmental
and regional expression [4] as well as in their biophysical
properties [5–6]. As a consequence, a growing body of
evidence suggests specific roles for GlyR isoforms in diverse
physiological processes [7-9].
GlyRs are also subject to allosteric modulation by metal ions
or small organic compounds including zinc, general anesthetics
and ethanol [3,10]. Two well characterized allosteric sites are
localized in the TM and ECD regions. Residues within the TM2
and TM3 domains of a1 GlyRs combine to form a cavity which
serves as an ethanol and general anesthetic binding pocket [11–
12], whereas several amino acids in the ECD contribute to the
modulation by zinc [13–14]. Interestingly, the GlyR isoforms
differ in their sensitivities to these modulators [15–17]. Recent
studies have reported that the GlyR activity can be modulated
allosterically by certain endocannabinoids (ECs) in a G-protein-
independent manner [10,18-20]. ECs are endogenous lipid
signaling molecules, structurally related to arachidonic acid,
that primarily, but not exclusively, act through G protein-
coupled cannabinoid receptors (CB-R) [21]. Interestingly, other
putative ECs and their synthetic derivatives, despite being poor
CB-R activators, are able to effectively modulate ion channels
[22–25]. ECs which modulate GlyRs not only spare GABAA-R
[19], but also exhibit differential effects on GlyR subtypes
[10,20]. Importantly, the sites for the EC modulation of GlyRs
have been shown to be different from the TM sites responsible
for ethanol modulation [19]. By analyzing different ECs in
chimeric and mutant GlyRs, we identified a group of residues
that jointly determine the EC sensitivity of GlyR isoforms.
These residues are localized along the N-terminal ECD, TM
and IL regions and are not related to previously known
allosteric sites on GABAA or GlyRs. Thus, our results define
hitherto unrecognized allosteric sites for ECs on GlyR, which
could possibly enable the development of subtype-specific GlyR
modulators.
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Results
Allosteric modulation of GlyR by endocannabinoid
derivatives
In a first set of experiments, we examined the sensitivity of the
three most abundant GlyR a subunits (a1, a2 and a3) to different
ECs. Most of these molecules have been identified as ECs or
putative ECs from brain or spinal cord extracts [21–22]. We found
that low micromolar concentrations of neutral and acidic ECs
modulated currents through homomeric GlyRs expressed in HEK
293 cells elicited at low glycine concentrations (EC10) (Figure 1,
Figure S1). Five of the compounds tested contained free carboxyl
groups (NA-Gly, N-arachidonoyl glycine; NA-Ser, N-arachidonoyl-
L-serine; NALA, N-arachidonoyl-L-alanine; NA-GABA, N-arachi-
donoyl-GABA; AA, arachidonic acid) and displayed subunit-
specificity. For example, NA-Gly induced a significant potentiation
of glycine-activated currents through a1 GlyRs by 101611%
(10 mM, n = 14), whereas currents through a2 or a3 GlyRs were
inhibited by25665% (n = 14) and by23263% (n = 14) at 10 mM,
respectively. On the other hand, the four hydroxylated, neutral
compounds (NOLE, noladin ether; AEA, anandamide; NA-5HT,
arachidonyl serotonin; NADA, N-arachidonyl dopamine) showed
consistent positive allosteric modulation of all the GlyR isoforms,
suggesting that carboxyl groups were required for the inhibition of
a2 and a3 GlyRs. Interestingly, the basic EC virodhamine (VIR),
which possesses an amino group instead of a hydroxyl or carboxyl
group, did not significantly alter the a2 and a3 GlyR responses and
behaved as a very weak a1 GlyR modulator (Figure 1A–C). These
results suggest that hydroxyl groups on ECs are required for the
positive modulation of all three GlyR isoforms, whereas carboxyl
groups are structural prerequisites for the inhibition of a2 and a3
GlyRs. These findings strongly suggest that the existence of specific
molecular sites in the different GlyR isoforms which underlie
subunit-specific actions of ECs on the GlyR subtypes.
Functional screening of endocannabinoid molecular sites
on GlyR
We next aimed at determining the molecular mechanisms and
elements underlying the differential allosteric modulation of GlyRs
by acidic ECs. To this end, we focused on NA-Gly and examined
its actions at different glycine concentrations (Figure S2).
Interestingly, the potentiation elicited by NA-Gly on a1 GlyRs at
EC10 of glycine was significantly attenuated at a higher glycine
concentration (EC50), whereas the NA-Gly-induced inhibition of
a2 and a3 GlyRs remained unaltered. These results suggest that
the mechanisms and molecular sites involved in potentiation and
inhibition are different and non-conserved between subunits. In
order to define the molecular sites involved, we next examined the
NA-Gly effects using a set of chimeric and mutant GlyRs. To
analyze the importance of TM4 and the IL domains, we first
studied a pair of chimeric GlyR constructs in which the regions
upstream of the IL between a1 and a2 were exchanged (Figure 2A).
We found that this exchange did not significantly affect the
modulation by NA-Gly (Figure 2B–C). Based on these results, we
can conclude that IL and TM4 domains do not significantly
contribute to the subunit-specific modulation by NA-Gly.
Next, we evaluated the importance of TM regions upstream from
the IL. Previous studies have shown that TM regions of GABAA and
GlyRs contain critical residues for several allosteric modulators,
such as ethanol, general anesthetics and neurosteroids [11–12,26–
27]. Furthermore, very recent evidences have been reported that
TM residues are critical for the potentiation of recombinant a1
GlyRs by D9-tetrahydrocannabinol (THC) and cannabidiol, two
phytocannabinoids [28–29]. Thus, a rational explanation for the
NA-Gly subunit-specific modulation could arise from differences in
TM domain composition. An amino acid sequence alignment of the
TM regions of a1 and a2 GlyR subunits revealed only 3 non-
conserved residues: I240, G254 and S296 in a1 GlyRs or A247,
A261 and A303 in a2 GlyRs (Figure 3A). To investigate the
contribution of these residues, we examined the NA-Gly-induced
potentiation of triple, double and single mutant a1 GlyRs in which
these amino acids have been substituted with their a2 GlyR
counterparts. Importantly, these mutated receptors as well as all
others described in this study responded normally to glycine
application (Table 1). Mutation of these non-conserved amino acids
(I240V/G254A/S296A) in a1 GlyR significantly reduced the GlyR
current potentiation by NA-Gly to 1466% (10 mM, n = 7).
Subsequent analyses using single and double mutated a1 GlyRs
demonstrated that the G254A mutation reduced the NA-Gly
modulation similarly (1769%, 10 mM, n = 8), indicating that G254
is a critical determinant of a1 GlyR potentiation (Figure 3B-D). At
higher agonist concentrations, no differences were found between
wild type and G254A a1 GlyRs. On the other hand, the reverse
A261G mutation in a2 GlyRs significantly attenuated NA-Gly-
induced inhibition at low and high glycine concentrations
(Figure 3D), indicating a role for this residue in both positive and
negative modulation of a1 and a2 GlyRs by NA-Gly. However, the
fact that this single mutation did not invert the potentiation into
inhibition or vice versa on both GlyRs suggests the existence of
other molecular sites that determine the final NA-Gly effects.
Many of the key residues involved in the coupling of agonist
binding to channel gating are located in the N-terminal ECD.
Several electrophysiological and molecular modeling studies have
postulated that residues within the loops 2 and 7 of the ECD
(terminology established by Brejc and coworkers) [30] are critical for
the events that precede channel gating [27]. In addition, recent
studies have proposed that the generation of a pre-open
conformation of the ion channel is a key determinant to explain
the differences between full and partial agonists on GlyRs [31].
Interestingly, a specific residue within the extracellular loop 2 of the
a1 GlyR (A52) has been implicated in the generation of this pre-
open conformation [32–33], and furthermore, mutation of this
amino acid into its a2 GlyR counterpart (A52S in human or A52T
in rat GlyRs) decreases the sensitivity to the allosteric effects of
ethanol [15,17]. Thus, it is possible that this residue may also
contribute to the NA-Gly effects on GlyRs and we directly
investigated its importance studying the NA-Gly sensitivity of
A52T a1 GlyRs and the reverse T59A a2 GlyR (Figure 4A). In a1
GlyRs, we found that this mutation significantly attenuated positive
modulation by NA-Gly, whereas the reverse substitution on a2
GlyRs did not change NA-Gly-induced inhibition (Figure 4B). At a
higher glycine concentration, these mutations did not significantly
affect the receptor sensitivity to this putative EC (Figure 4B).
Therefore, these results indicate that only the positive allosteric
modulation elicited by NA-Gly on a1 GlyRs required the A52
residue. However, these mutations again did not convert the current
potentiation into inhibition or vice versa, suggesting that the
extracellular and TM domain elements identified here could jointly
determine the NA-Gly sensitivity of both GlyR isoforms.
To explore this idea, we studied receptors in which both TM and
loop 2 residues were exchanged (Figure 5A–C). These experiments
showed that in a2 GlyRs, the combined reversal T59A/A261G
significantly reduced NA-Gly-induced inhibition to 2466%
(10 mM, n = 10), but still did not change the direction of modulation.
Surprisingly, the incorporation of the reversal A303S substitution
into this double-mutated GlyR was able to convert NA-Gly from an
inhibitor to an allosteric potentiator (4465%, 10 mM, n = 10)
(Figure 5A–C). At a higher glycine concentration, the NA-Gly-
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Figure 1. Modulation of different GlyR subtypes by ECs. (A) Glycine-activated membrane currents through wild-type a1, a2 and a3 GlyRs
under control conditions (black) and in the presence of AEA, NA-Gly and VIR (red; all 10 mM). Membrane currents were activated by equipotent (EC10)
glycine concentrations for each particular subunit. Chemical structures for the ligands are also shown. (B) Concentration-response curves. (C)
Summary of the EC-mediated allosteric modulation of GlyRs subunits obtained at 10 mM concentration. Note that all acidic ECs tested still
potentiated the a1 GlyR currents, but inhibited currents through a2 - a3 GlyRs. NOLE, noladin ether; AEA, anandamide; NA-5HT, arachidonyl serotonin;
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induced inhibition on a2 GlyRs was also significantly attenuated
(Figure 5D). On the other hand, 10 mM of NA-Gly did not inhibit
a1 GlyRs containing the reverse mutations (A52T/G254A/S296A)
at EC10 of glycine, but showed a partial inhibition at EC50
(Figure 5C). These results suggest that the potentiating effects of
NA-Gly on a1 GlyRs are mainly determined by the residues A52T/
G254A/S296A, whereas the negative effect depends on unidenti-
fied molecular determinants only present in a2, but not in a1 GlyRs.
In order to investigate if these molecular determinants can also
reverse the inhibitory actions of NA-Gly on a3 GlyRs, we first
performed amino acid sequence alignments of loop 2 and the
critical TM regions. These analyses revealed only one residue, on
TM2, which was not conserved between a1 and a3 GlyRs (G254
in a1, A261 in a2 and A265 in a3, Figure 6A). Taking into account
the findings described in Figure 5, it seems fair to suggest that the
introduction of the point-mutation A265G in a3 GlyRs should be
sufficient to convert the NA-Gly-mediated inhibition into a
potentiation. Introduction of the A265G mutation in a3 GlyR
significantly reduced the GlyR current inhibition by NA-Gly (-
864%, 10 mM, n = 6) but did not convert the inhibition into
potentiation (Figure 6B-C). At higher agonist concentrations, this
mutation also significantly attenuated NA-Gly-induced inhibition
(Figure 6C), indicating a common role of this residue in the
negative modulation of a2 and a3 GlyRs at low and high glycine
concentrations (see also Figure 3).
These observations demonstrate that residues in extracellular
and TM domains jointly determine the positive modulation of a1
GlyRs by NA-Gly, and suggest that acidic ECs could share similar
mechanisms of action on these receptors. On the other hand, the
current inhibition induced by NA-Gly appears to be largely
determined by the nature of the 29 residue in the TM2 of a2 and
a3 GlyRs (A261 and A265, respectively). However, all these
residues appear dispensable for potentiation by hydroxylated ECs
(compare Figure 1). Thus, these results indicate that other residues,
possibly conserved between the GlyR isoforms, should be critical
for the positive allosteric modulation by neutral ECs.
A basic intracellular residue is critical for the positive
endocannabinoid allosteric modulation of GlyRs
The results presented above suggest that none of the known
ECD and TM molecular sites for allosteric modulators are
responsible for the positive modulation by hydroxylated ECs on
Figure 2. NA-Gly effects on chimeric GlyR constructs. (A) Schematic depiction of wild type and chimeric GlyRs. (B) Examples of whole-cell
currents recorded from a1a2 or a2a1 GlyRs before (black) and during the application of NA-Gly (10 mM, red). (C) Percent change of the normalized
glycinergic membrane currents during the application of NA-Gly (10 mM) using equipotent (EC10) glycine concentrations. The exchange of the IL
between TM3 and TM4 plus the TM4 domain between a1 and a2 GlyRs did not significantly influence the NA-Gly-induced modulation.
doi:10.1371/journal.pone.0023886.g002
NADA, N-arachidonyl dopamine, NA-Gly; N-arachidonyl glycine; NA-GABA, N-arachidonyl-GABA; NA-Ser, N-arachidonoyl-L-serine; NALA, N-
arachidonoyl-L-alanine; AA, arachidonic acid; VIR, virodhamine. Data are means 6 SEM from 6-15 cells.
doi:10.1371/journal.pone.0023886.g001
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GlyRs. In addition, since AEA effects on GlyRs appear to be
different than those TM elements described for ethanol and
general anesthetics (S267 in TM2 domain, see ref. [19]), it appears
possible that some conserved key residues outside the TM domains
are likely to be responsible for the EC effects on GlyRs. Recent
studies have explored the role of the large TM3-4 IL for the Cys-
loop ion channel function, intracellular regulation and pharma-
cology. Electrophysiological studies showed that basic residues
within the IL of 5-HT3 receptors are critical determinants of single
channel conductance [34], whereas other intracellular basic
residues on GlyRs are critical for direct G protein bc interaction
with the ion channel [35]. In GlyRs, the same basic residues are
required for the allosteric effects of ethanol [36], demonstrating
that intracellular residues, besides TM amino acids, can contribute
to allosteric modulation of GlyRs. Amino acid sequence alignment
of the IL revealed that the most critical lysine residue for Gbc
modulation of a1 GlyRs is fully conserved between the three GlyR
isoforms (K385 in a1 GlyRs, Figure 7A). Thus, in order to
examine if this amino acid plays a role in the modulation by ECs,
we first tested the sensitivity to NA-Gly of K385A mutated GlyRs
at EC10 glycine (Figure 7B–C). Our results show that the
intracellular K385A mutation significantly attenuated the poten-
tiation by NA-Gly on a1 GlyRs to 1464% (5 mM, n = 8), which is
similar to those obtained after mutation of extracellular or TM
residues (Figure 3–4). In addition, the homologous intracellular
mutations (named K385A relative to a1 GlyR sequence) did not
significantly alter the current inhibition induced by 10 mM of NA-
Gly on a2 (25964%, n = 8) or a3 GlyRs (24064%, n = 7). The
mutation of this residue furthermore did not alter the NA-Gly
inhibitory effects at higher glycine concentrations, indicating a
selective effect on the positive allosteric effects on a1 GlyRs
(Figure 7C). This selectivity was further confirmed in experiments
performed in the triple mutated T59A/A261G/A303S a2 GlyRs,
which are potentiated by NA-Gly (Figure 5). In these receptors,
the mutation of the conserved basic lysine residue significantly
attenuated the NA-Gly potentiation at EC10 glycine (2165%,
10 mM, n = 5, Figure S3) but did not alter the modulation at high
glycine concentration (Figure S3).
Because the intracellular lysine residue K385 is conserved
between GlyR isoforms and its mutation was able to selectively
attenuate the positive allosteric effects of an acidic EC on a1 GlyRs
and on the triple mutated T59A/A261G/A303S a2 GlyRs, it
appears likely that this residue could play a critical role in the
potentiation elicited by neutral ECs, which is similar between the
three subunits examined (Figure 1). We therefore investigated the
effects of two hydroxylated ECs on GlyRs with mutations in the
K385 residue (Figure 8A-E). The mutated K385A a1 GlyR was
significantly less potentiated by AEA (1463%, n = 8, 5 mM). In
subsequent experiments we found that the homologous mutations
in a2 and a3 GlyRs also attenuated AEA-induced potentiation
(965%, n = 7 and 1965%, n = 6, 5 mM, respectively), demon-
strating a critical role for this amino acid in the positive
modulation by AEA in all three GlyR subtypes (Figure 8E).
Further analyses showed that the positive modulation by NA-
5HT, a synthetic EC analog [24], was also significantly attenuated
in K385A-mutated a1, a2 and a3 GlyRs (Figure 8C–E). These data
demonstrate that the K385 residue is critical for the positive
allosteric modulation of all the GlyR isoforms by both acidic and
neutral EC derivatives, but appears to be dispensable for the
inhibitory actions of acidic ECs on a2 and a3 GlyRs.
Discussion
Previous studies have identified molecular sites for relevant
neuromodulators within GlyRs and GABAARs subunits. Molec-
ular sites for ethanol and volatile anesthetics on a1 GlyR have been
localized in the interface between the TM2 and TM3 domains,
whereas acceptor sites for zinc have been identified in the ECD
[12–14]. Other reports have identified allosteric sites for etomidate
and propofol within the TM2-3 domains of b2 and b3 GABAARs
subunits and critical residues for neurosteroid effects on TM1 and
TM4 regions of a1 GABAARs [27]. Only very recent studies have
addressed sites for several cannabinoid ligands on GlyRs. These
studies have shown that specific TM residues (S267 and S296 in a1
GlyRs) are important for the potentiation elicited by some
Table 1. Electrophysiological properties of wild-type and
mutated GlyRs.
Construct EC50 (mM) nH Imax (pA) n
a1 WT 6861 2.560.09 41136491 8
a2 WT 12066 1.860.15 31336378 7
a3 WT 16668 1.960.16 14466331 12
a1a2 8663 2.360.14 37816801 5
a2a1 11161 2.460.12 44426845 5
a1 I240V/G254A/S296A 3761* 2.560.11 67266989 5
a1 I240V/G254A 3262* 1.960.20 34476666 5
a1 G254A/S296A 7363 1.960.12 33436990 5
a1 I240V 6361 2.460.11 52856787 5
a1 G254A 4361* 2.560.08 50266578 6
a1 S296A 8461 2.260.06 48526507 5
a2 A261G 21766* 2.160.10 31856678 6
a3 A265G 30664* 2.360.05 18736284 7
a1 A52T 19564* 2.260.10 52436910 5
a2 T59A 6361* 2.260.05 32706678 5
a2 T59A/A261G 7662* 2.260.10 362861429 5
a2 T59A/A261G/A303S 10262 2.160.08 34776995 5
a2 T59A/A261G/A303S/K385A 4861* 2.260.09 477761331 6
a1 A52T/G254A/S296A 10364* 2.160.15 495761214 6
a1 K385A 4363* 2.260.24 34746505 8
a2 K385A 7662* 1.660.07 34096569 8
a3 K385A 10763* 2.560.12 20646575 7
Values are indicated as mean 6 s.e.m. from the indicated number of cells.
*indicates significant difference (P,0.05, ANOVA) against the corresponding
wild type GlyR subtype.
doi:10.1371/journal.pone.0023886.t001
Figure 3. Positive and negative NA-Gly allosteric effects on a1 and a2 GlyRs are influenced by a single TM2 domain residue. (A)
Primary sequence alignment between a1 and a2 GlyR subunits from TM1 to TM3 regions. The 3 non-conserved residues are highlighted by green
boxes. (B) Examples of current traces through GlyRs with mutated TM domains, in absence (black) or presence of NA-Gly (red) (C) The bar graphs
summarizes the normalized glycine-evoked current enhancement after the application of 10 mM NA-Gly on a1 GlyRs with mutations in specific
residues within the TM domains (D) Schematic representation of wild-type and TM2-mutated GlyRs (E) Concentration-response curves for NA-Gly in
wild-type and TM-mutated a1 and a2 GlyRs using two different agonist concentrations. Note that the specific mutation G254A in a1 GlyRs significantly
attenuated the EC potentiation, whereas the reverse TM2 mutation in a2 GlyRs (A261G) additionally decreased the NA-Gly-induced inhibition.
doi:10.1371/journal.pone.0023886.g003
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phytocannabinoids (e.g. D9-tetrahydrocannabinol (THC) or can-
nabinodiol) on GlyRs [10,28–29]. Whether these molecular sites
affect the cannabinoids actions by interfering with allosteric
mechanisms or by affecting their binding is still a matter of debate.
Mutations to the S267 residue in a1 GlyRs affect the actions of
several other allosteric modulators probably by altering their
Figure 4. The composition of extracellular loop 2 influences the NA-Gly-induced potentiation of a1 GlyRs. (A) Amino acid sequence
alignment between a1 and a2 GlyRs within the extracellular loop 2. The A52 residue in a1 GlyRs and their homologous position in a2 GlyRs are
highlighted by a green box. (B) Schematic depictions of GlyRs with point mutations in the extracellular loop 2 (C) Concentration-response curves for
NA-Gly in wild-type and extracellular loop 2-mutated a1 and a2 GlyRs using two different agonist concentrations. The mutation A52T significantly
attenuated the NA-Gly sensitivity of a1 GlyRs, whereas the reverse mutation in a2 GlyRs (T59A) did not alter NAGly-induced inhibition.
doi:10.1371/journal.pone.0023886.g004
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Figure 5. Selective extracellular loop 2 and TM domain mutations in a2 GlyRs convert NA-Gly into an allosteric potentiator. (A)
Examples of glycine-activated current traces from wild-type a1 and mutant a2 T59A/A261G/A303S GlyRs in the presence of NA-Gly (in red) (B)
Summary of the effects of NA-Gly after simultaneous extracellular loop 2 and TM reverse mutations on a2 GlyRs (*** P,0.001, vs a2 GlyRs) (C)
Schematic diagrams of the triple mutated a1 and a2 GlyRs (D) Sensitivity of the normalized glycine-activated currents elicited in wild-type and triple
mutated GlyRs to different concentrations of NA-Gly. Note that three simultaneous reverse mutations in a2 GlyR converted NA-Gly into an allosteric
potentiator, whereas the homologous substitutions within a1 GlyR still did not produce a significant inhibition.
doi:10.1371/journal.pone.0023886.g005
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binding [10–12,27]. The importance of this residue for the
cannabinoid modulation has been addressed by two groups with
conflicting results. While the mutation S267I abolishes the
potentiation by cannabidiol and HU210 [28], the S267Q
substitution did not change the current enhancement induced by
THC or AEA [19]. In this context, the role of the S296 residue in
a1 GlyRs appears more specific. It has been recently characterized
as a pivotal element for THC binding, and furthermore, its
mutation did not alter the GlyR sensitivity to other allosteric
modulators, such as propofol [29]. In the present study, we have
identified residues in the GlyR critical for the positive and negative
allosteric modulation by ECs (summarized in Figure 9).
Electrophysiological studies on different wild-type GlyR sub-
types identified distinct actions of different ECs, supporting the
idea that determinants present on the EC chemical structures plus
the existence of specific acceptor sites determine the final allosteric
effects [10,20,29]. Our results with mutated GlyRs support a role
for the A52 and G254 residues in the potentiation of a1 GlyRs by
acidic ECs. Our finding that successive reverse mutations on the
non-conserved extracellular loop 2 and TM residues in a2 GlyRs
converted the inhibitory effect of NA-Gly into potentiation further
supports the idea that the extracellular loop 2 and TM residues are
essential elements for the positive allosteric effects of acidic ECs.
These results however should be interpreted with some caution.
The presence of equivalent loop 2 and TM compositions in a3
GlyRs significantly attenuated the NA-Gly inhibitory effect, but
did not turn the NA-Gly inhibition into potentiation. In addition,
our experiments with mutated a1 GlyRs did not show any
significant NA-Gly-induced inhibition. Our results thus suggest
that the positive and negative actions of acidic ECs on different
Figure 6. The negative allosteric effects of NA-Gly on a3 GlyRs were attenuated but not reverted by altering the TM2 domain
composition. (A) Primary sequence alignment of a1, a2 and a3 GlyR subunits in selected extracellular loop 2, TM2 and TM3 segments (B) Schematic
depiction of wild type and point mutated a3 GlyRs. (C) Examples of current traces through wild-type and point-mutated a3 GlyRs in absence (black) or
presence of NA-Gly (10 mM, red) (D) Concentration-response curves for NA-Gly in wild-type and TM2-mutated a3 GlyRs using two different glycine
concentrations. Note that this specific mutation A265G in a3 GlyRs significantly attenuated the NA-Gly-induced inhibition, but did not convert the
inhibition into potentiation
doi:10.1371/journal.pone.0023886.g006
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GlyR subunits are determined by the combination of several
molecular sites in each GlyR subunit. Despite the fact that some of
these sites are still not identified, it is plausible that the NA-Gly
induced inhibition of a2 and a3 GlyRs occurs through similar
mechanisms and molecular sites.
The residues identified in our experiments could affect the
acidic EC modulation of GlyRs through different mechanisms.
The extracellular loop 2 residue may influence the EC effects by
altering the ion channel conformation during pre-open states [31–
33], whereas the TM residues could either alter putative binding
sites [12,29] or affect the ion channel gating [3–5]. Regarding
these two TM residues, our data show that only the TM residue at
position 29 within the TM2 helix (G254 on a1 GlyR, A261 on a2
GlyR, and A265 on a3 GlyR) was involved in both NA-Gly-
induced potentiation and inhibition. Conversely, the non-con-
served TM3 residue (S296 on a1 GlyR, A303 on a2 GlyR, and
Figure 7. The positive allosteric modulation elicited by NA-Gly is influenced by a conserved lysine residue within the a1 GlyR large
intracellular loop. (A) The schematic receptor representation and the primary sequence alignment describe the position of the conserved
intracellular K385 residue within the GlyR structure (B) Glycine-activated current traces from wild-type or K385A-mutated a1 GlyRs before (black) and
during the application of NA-Gly (5 mM, red) (C) Concentration-response curves for NA-Gly obtained from wild-type and K385-mutated GlyRs. The
intracellular mutation significantly attenuated the NA-Gly-induced potentiation of a1 GlyRs.
doi:10.1371/journal.pone.0023886.g007
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Figure 8. A conserved intracellular lysine residue determines the positive allosteric modulation by neutral ECs on GlyRs. (A)
Examples of current traces through wild-type a1 GlyRs and K385A mutated GlyRs in absence (black) or presence of AEA (5 mM, red) (B) Sensitivity to
AEA of the normalized glycine-activated currents in wild-type and K385A-mutated GlyRs. The intracellular mutation effectively attenuated the AEA-
induced modulation of the three GlyR subunits. (C) Glycine-activated current traces from wild-type or K385A-mutated a1 GlyRs before (black) and
during the application of NA-5HT (5 mM, red) (D) Concentration-response curves for NA-5HT obtained from wild-type and K385-mutated a1 GlyRs (E)
Summary of the allosteric effects elicited by AEA and NA-5HT in wild-type and K385A-mutated GlyRs. The current potentiation was significantly
attenuated by the intracellular mutation. ***, P,0.001 between each wild-type GlyR and its corresponding K385A mutant.
doi:10.1371/journal.pone.0023886.g008
Figure 9. Molecular sites for the allosteric modulation of different GlyR subtypes by ECs. The schematic diagram summarizes the
molecular sites for the allosteric modulation of GlyRs by acidic and neutral ECs. The inhibition of a2 and a3 GlyRs elicited by NA-Gly was specifically
influenced by a single TM2 residue (A261 in a2 GlyRs and A265 in a3 GlyRs), whereas the NA-Gly-induced potentiation of a1 GlyRs was reduced by
mutating loop 2 (A52), TM2 (G254) or intracellular (K385) amino acids. On the other hand, the AEA-induced potentiation of these three GlyR subtypes
was reduced by mutating a conserved intracellular lysine residue (K385 in a1 GlyRs).
doi:10.1371/journal.pone.0023886.g009
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A307 on a3 GlyR) did not influenced NA-Gly potentiation on a1
GlyRs but was necessary to switch the NA-Gly inhibition into
potentiation on a2 GlyRs. Thus, these findings suggest that the 29
residue is essential for the allosteric mechanism or for the binding
of NA-Gly to the receptor structure, while the TM3 residue likely
participates in the allosteric mechanism required for NA-Gly
potentiation exclusively on a2 GlyRs. Interestingly, a recent report
proposed a role for S296 on a1 GlyR and A307 on a3 GlyRs in the
direct binding of THC to TM3 domains possibly via hydrogen
bond interactions [29]. Whether the mutations analyzed in our
studies preferentially alter acidic EC binding sites or the allosteric
mechanisms involved is at present uncertain. However, our results
appear to support the fact that part of the positive and negative
NA-Gly effects occur in the TM2 region close to the intracellular
vicinity of the ion channel pore, whereas loop 2 may regulate these
functional modulations through allosteric effects associated to pre-
open states of the ion channel.
On the other hand, our results analyzing the potentiation
elicited by neutral ECs on GlyRs showed that the non-conserved
TM2 and TM3 amino acids between the GlyRs are essentially
dispensable. In this context, the pivotal role of the conserved
intracellular K385 residue for the positive allosteric effects of both
acidic and neutral ECs supports the idea that this residue is
essential for the allosteric mechanism behind the GlyR potenti-
ation by ECs. The unchanged NA-Gly-induced inhibition
displayed by a2 and a3 K385A mutants and the lack of inhibition
displayed by the reverse a1 mutants also suggests that the sites for
the positive and negative effects of acidic ECs on GlyRs are
different. Based on these results, we propose that the positive EC
allosteric site appears to be present in all three GlyR subtypes and
is likely to lie in the region between the IL and the TM4 domain in
close contact with the lipid-water interface. In contrast, the
inhibitory action of acidic ECs appears to be linked related to TM
elements present exclusively on a2 and a3 isoforms and apparently
exerts dominance over the positive allosteric site on these GlyR
subunits. Together with data from previous studies [3–4,11–
13,27], our data suggest that the putative molecular sites for ECs
on GlyRs are distinct from previously identified allosteric sites for
on GABAA and GlyRs. In addition, our results indicate that the
putative molecular TM sites for THC derivatives [28-29] and the
EC sites on GlyRs are essentially different and apparently
unrelated.
There is a large body of evidence to suggest that ECs can elicit
CB-R independent actions on ion channels [37]. The Cys-loop
family is a particularly well characterized target of ECs [38].
Although our results challenge previous reports in some respects
[18,20], they strongly support the main conclusion of previous
reports that ECs may constitute a family of endogenous GlyR
modulators with potential impact on the control of neuronal
excitability. Our findings on the subunit selectivity and the
molecular sites involved provide additional important insights.
First, the critical role of the intracellular lysine residue suggests that
these effects can be fine tuned by intracellular signaling or post-
translational modifications. Intracellular events such as G protein
activation [35–36], ubiquitination [39–40], changes in membrane
composition or interactions with accessory proteins may influence
the sensitivity of the GlyR subtypes to ECs. Thus, these
intracellular events likely contribute to the variability observed in
the EC effects on GlyRs. Second, the presence of a modulatory site
on the IL matches the intracellular accumulation of ECs reported
by others [41]. Several ECs are produced in areas where GlyRs
are expressed and their levels also appear to be altered during
pathological states, such as spinal cord injury [22,42–44]. Thus,
the EC-GlyR interaction could represent a relevant mechanism for
the control of inhibitory glycinergic transmission in the spinal cord
during pathological conditions, such as chronic pain. Third, the
basic character of the key lysine residue and the structure-activity
relationship of ECs on GlyRs suggest that the head groups of the
hydroxylated and acidic ECs could directly interact with the K385
amino acid. Interestingly, recent studies have highlighted the
interaction of TM4 domain with anionic and neutral lipids in
other pentameric ligand-gated ion channels [45–46]. Moreover,
ECs likely acquire an extended conformation in the lipid bilayer
with their polar group in close proximity to the membrane
phospholipid head groups and the water-lipid interface [47].
Although the data presented here does not provide direct proof,
together with the aforementioned reports, we can hypothesize that
the lipid surrounded surface of TM4 domains could act as an
acceptor of the EC alkyl chains, whereas the IL region that
contains the K385 residue could configure the interaction zone
with the EC head groups via non-covalent interactions. Predicting
whether these residues are also directly involved in EC binding is
extremely difficult in the absence of crystal structures for GlyRs. It
will therefore be interesting to further map the residues within
TM4 and IL that may influence the EC allosteric modulation of
GlyRs.
In summary, our results provide previously unrecognized
molecular sites for the allosteric interaction of ECs with GlyRs.
The specific contribution of this interaction to physiology and
pathology may in the future become accessible through the
generation of gene-targeted mice carrying mutations in the
molecular sites identified in the present study. A very recent study
has suggested that the positive allosteric modulation exerted by
THC on GlyRs is highly relevant for cannabinoid-induced
analgesia in animal models of pain, suggesting that several others
cannabinoid ligands could represent a promising strategy to
develop new pain therapeutics [29]. Thus, a more precise
knowledge of the EC sites on GlyRs may in addition provide
additional rational basis for the development of novel analgesic
drugs acting at specific GlyR subtypes.
Materials and Methods
Cell Culture and Transfection
HEK 293 cells (CRL-1573; American Type Culture Collection,
Manassas, VA, USA) were cultured using standard methods and
were transfected using Lipofectamine LTX (Invitrogen, Carlsbad,
CA, USA) with 2 mg of DNA for each GlyR and 0.5 mg of EGFP.
Expression of EGFP was used as a marker of successfully
transfected cells. All recordings were made 18–36 hours after
transfection.
Electrophysiology
Glycine-evoked currents were recorded from transfected HEK
293 cells in the whole-cell voltage-clamp configuration at room
temperature (20–24uC) at a holding potential of 260 mV. Patch
electrodes were pulled from borosilicate glass and were filled with
(in mM): 120 CsCl, 10 EGTA, 10 HEPES (pH 7.4), 4 MgCl2, 0.5
GTP and 2 ATP. The external solution contained (in mM) 150
NaCl, 10 KCl, 2.0 CaCl2, 1.0 MgCl2, 10 HEPES (pH 7.4), and
10 glucose. Recordings were performed with a HEKA EPC-7
amplifier and Patch Master v2.11 software (HEKA Elektronik,
Lambrecht-Pfalz, Germany). The amplitude of the glycine current
was obtained using a manually applied pulse (3-6 s) of a sub-
saturating glycine concentration (EC10 or EC50) for each GlyR
subunit, using an outlet tube (200 mm ID) of a custom-designed
gravity-fed microperfusion system positioned 50–120 mm of the
recorded cell. EC10 or EC50 values for each GlyR studied were
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obtained experimentally after successive application of 1, 10, 30,
60, 100, 200, 500 and 1000 mM glycine (Table 1). The
concentration-response curves parameters (EC50 and Hill coeffi-
cients, nh) were obtained from the curve fits of normalized
concentration–response to the equation Igly = Imax (gly)nh/((gly)nh
+ (EC50)nh). The mean maximal current (Imax) indicated the
average maximal current elicited by a concentration of 1 mM
glycine. All modulators were first dissolved in ethanol, DMSO,
methanol or methyl-acetate and subsequently diluted into the
recording solution on the day of the experiment. None of the
vehicles produced discernable effects on the glycine-evoked
currents. The drugs were co-applied with glycine, without pre-
applications. EC effects were tested up to 10 mM in order to avoid
significant membrane-associated effects [48–49].
cDNA Constructs
Mutations were inserted using the QuickChangeTM site-
directed mutagenesis kit (Stratagene, La Jolla, CA, USA) in
cDNA constructs encoding GlyRs in a pCI vector (Promega,
Madison, WI, USA) or pcDNA3 (Invitrogen, Carlsbad, CA, USA).
All the constructions were confirmed by full sequencing. The
procedures involved in the generation of the chimeric GlyRs have
been previously published [17]. The GlyR amino acids were
numbered according to their position in the mature protein
sequence.
Chemicals
All the drugs were obtained from Tocris Bioscience (Bristol,
UK) or BioTrend AG (Zurich, CH). N-arachidonoyl-L-alanine
(NALA), N-arachidonoyl-L-serine (NA-Ser) and arachidonic acid
(AA) were purchased from Cayman Chemical (Ann Arbor, MI,
USA).
Data analysis
All values were expressed as mean 6 s.e.m of normalized
glycine-activated currents. Statistical comparisons were performed
using ANOVA. P,0.05 was considered statistically significant.
For statistical analysis, at least 6 cells were analyzed. For all the
statistical analysis and plots, MicroCal Origin 6.0 (Northampton,
MA, USA) software was used.
Supporting Information
Figure S1 Endocannabinoid sensitivity of different GlyR
subtypes. Concentration-response curves for ECs in wild-type
a1, a2 and a3 GlyRs. Membrane currents were activated by
equipotent (EC10) glycine concentrations. Chemical structures for
the ligands are also shown. NOLE, noladin ether; AEA,
anandamide; NA-5HT, arachidonyl serotonin; NADA, N-arachi-
donyl dopamine, NA-Gly; N-arachidonyl glycine; NA-GABA, N-
arachidonyl-GABA; NA-Ser, N-arachidonoyl-L-serine; NALA, N-
arachidonoyl-L-alanine; AA, arachidonic acid; VIR, virodhamine.
Data are means 6 SEM from 6-15 cells.
(TIF)
Figure S2 Concentration-response curves for NA-Gly on
wild-type GlyR subunits at different glycine concentra-
tions. Glycine-evoked currents were activated by glycine at EC10
or EC50 concentrations and then tested in the presence of NA-Gly.
These values were calculated from experimental concentration–
response curves (Table 1). Note that the effects of NA-Gly on a1
GlyRs were significantly attenuated at a higher glycine concen-
tration, whereas the inhibitory actions of NA-Gly on a2 and a3
GlyRs were unaffected.
(TIF)
Figure S3 The potentiation elicited by NA-Gly on the
triple mutated a2 T59A/A261G/A303S GlyRs also re-
quire a lysine residue within the large intracellular loop.
(A) Schematic depiction of wild type and mutated a2 GlyRs. (B)
Concentration-response curves of the normalized glycine-activated
currents elicited in wild-type and triple or quadruple mutated a2
GlyRs to different concentrations of NA-Gly using an EC10 or an
EC50 of glycine. Three simultaneous reverse mutations in a2 GlyR
converted NA-Gly into an allosteric potentiator. This current
enhancement was significantly attenuated by the mutation of a
conserved lysine residue in the large intracellular loop (K385A).
(TIF)
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